Clinical Trial Update: A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating allogeneic CD19-CAR-T cells for relapsed/refractory B-cell hematologic malignancies, with recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• Allogenic CD19-CAR-T (CD19-CAR-T)

Snippet

Sponsor: YANRU WANG | Conditions: Hematologic Malignancies, Lymphoma | Phase 1 | Status: NOT_YET_RECRUITING